Clinical Characteristics and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement: The TriACT Registry.

Hagemeyer, Daniel; Merdad, Anas; Sierra, Laura Villegas; Ruberti, Andrea; Kargoli, Faraj; Bouchat, Marine; Boiago, Mauro; Moschovitis, Aris; Deva, Djeven P; Stolz, Lukas; Ong, Geraldine; Peterson, Mark D; Piazza, Nicolo; Taramasso, Maurizio; Dumonteil, Nicolas; Modine, Thomas; Latib, Azeem; Praz, Fabien; Hausleiter, Jörg and Fam, Neil P (2024). Clinical Characteristics and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement: The TriACT Registry. JACC. Cardiovascular Interventions, 17(4), pp. 552-560. Elsevier 10.1016/j.jcin.2023.12.016

Text 1-s2.0-S1936879823016527-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (325kB) | Request a copy

BACKGROUND

Transcatheter tricuspid valve replacement (TTVR) abolishes tricuspid regurgitation (TR) and has emerged as a definitive treatment for TR.

OBJECTIVES

The purpose of this multicenter, observational study was to determine the clinical characteristics and short-term outcomes of patients with TR screened for TTVR.

METHODS

Patients underwent TTVR screening at 7 centers on a compassionate-use basis. The primary endpoints were NYHA functional class and TR grade at 30-day follow-up. Secondary endpoints included all-cause mortality, heart failure hospitalization, technical success, and reasons for TTVR screening failure.

RESULTS

A total of 149 patients (median age 79 years [Q1-Q3: 72-84 years], 54% women) underwent TTVR screening. The TTVR screening failure rate was 74%, mainly related to large tricuspid annular diameter. Patients undergoing TTVR (n = 38) had significant functional improvements (NYHA functional class I or II from 21% to 68%; P < 0.001), with TR ≤1+ in 97% at 30-day follow-up (P < 0.001 from baseline). Technical success was achieved in 91%, with no intraprocedural mortality or conversion to surgery. At 30-day follow-up, mortality was 8%, heart failure hospitalization 5%, major bleeding 18%, and reintervention 9%. Patients who failed screening for TTVR and subsequently underwent "bailout" transcatheter edge-to-edge repair (n = 26) had favorable outcomes (NYHA functional class I or II from 27% to 58%; P < 0.001), with TR ≤1+ in 43% at 30-day follow-up (P < 0.001 from baseline).

CONCLUSIONS

This first real-world report of TTVR screening demonstrated a high screening failure rate, mainly related to large tricuspid annular diameter. Patients undergoing TTVR had superior TR reduction and symptom alleviation compared with bailout tricuspid transcatheter edge-to-edge repair, at the cost of greater procedural complications.

Interest & Impact

Downloads

0 since deposited on 19 Mar 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item